Gapping up
In reaction to strong earnings/guidance: PDEX +14.1%, AKS +8.2%, ZAYO +2.8%, KUTV +2.7%
Other news: SFXE +19.7% (cont strenght after co secured $60 mln in new financing and refinances its existing $30 mln revolving credit facility yesterday), VBLT +15.7% (announces that complete Phase 2 data on VB-111, in combination with Bevacizumab will be presented at the European Society for Medical Oncology's (ESMO) European Cancer Congress ), MTL +4.9% (still checking), SFUN +4.3% (announces a $400 to $700 mln investment from IDG, Carlyle and management members), RXDX +1.5% (announces initiation of Phase 1/1b clinical trial of RXDX-107 in patients with locally advanced or metastatic solid tumors ), KGC +1.2% (lowered guidance for all-in sustaining cost per gold equivalent ounce sold to $975-1025 from $1000-1100; lowers CapEx guidance to $650 mln from $725 mln), ARW +0.7% (announced authorization for an additional $400 million in repurchases, via its common share repurchase program)
Analyst comments: CEMP +3.6% (announces the FDA has granted qualified infectious disease product designation to Taksta), GSBD +0.7% (upgraded to Outperform from Mkt Perform at Raymond James)
In reaction to strong earnings/guidance: PDEX +14.1%, AKS +8.2%, ZAYO +2.8%, KUTV +2.7%
Other news: SFXE +19.7% (cont strenght after co secured $60 mln in new financing and refinances its existing $30 mln revolving credit facility yesterday), VBLT +15.7% (announces that complete Phase 2 data on VB-111, in combination with Bevacizumab will be presented at the European Society for Medical Oncology's (ESMO) European Cancer Congress ), MTL +4.9% (still checking), SFUN +4.3% (announces a $400 to $700 mln investment from IDG, Carlyle and management members), RXDX +1.5% (announces initiation of Phase 1/1b clinical trial of RXDX-107 in patients with locally advanced or metastatic solid tumors ), KGC +1.2% (lowered guidance for all-in sustaining cost per gold equivalent ounce sold to $975-1025 from $1000-1100; lowers CapEx guidance to $650 mln from $725 mln), ARW +0.7% (announced authorization for an additional $400 million in repurchases, via its common share repurchase program)
Analyst comments: CEMP +3.6% (announces the FDA has granted qualified infectious disease product designation to Taksta), GSBD +0.7% (upgraded to Outperform from Mkt Perform at Raymond James)